Furthermore, the disruption of the guanylin–GC-C pathway in IBD may be confirmed by the research of Brenna et al. [19], in which decreased expression of guanylin, together with reduced GC-C signaling, was noted in biopsies collected from patients with IBD. The gene discussed is GUCY2C; the disease is inflammatory bowel disease.